Healthcare Innovation

What Healthcare Innovation does

Healthcare Innovation Co., Ltd. (株式会社ヘルスケア・イノベーション) is a Tokyo-based venture capital firm established in February 2017 by Yoshihiro Otaki (大滝 義博, Representative Director and Chairman) and Mitsuru Miyata (宮田 満, Representative Director and President), with stated capital of ¥10 million and a headcount reported as 1-10 employees. The firm manages the Healthcare Innovation First Fund (ヘルスケア・イノベーション第一号ファンド), positioned in its own materials as Japan's first bio/healthcare-focused VC fund explicitly targeting the middle-stage investment gap in the Japanese bio ecosystem. It allocates approximately 70% of investment capital to pre-IPO bio ventures and 30% to ventures or founders with revolutionary technology or product seeds, screening from a Japanese bio venture universe the firm estimates at over 500 companies.

The firm's core product is fund management delivered through direct engagement with bio ventures. Prospective portfolio companies submit information through the member portal (member.hcinnovation.jp), and qualified applicants proceed to 30-minute face-to-face consultations. The portfolio spans at least 18 companies across multiple bio sub-sectors including CAR-T cell therapy (Noile-Immune Biotech, Rebirthel, ARC Therapies), gene therapy (CellGenTech, Gene Therapy Research Institution, RegeNephro), antibody drugs (EVEC, NB Health Laboratory, AutoPhagyGO), digital therapeutics (CureApp, SUSMED), drug delivery (United Immunity), and platform technologies (PRISM BioLab, Luxna Biotech, TAGCyx, GEXVal). Many portfolio companies originate from Japanese universities including Kyoto, Osaka, Chiba, Yamaguchi, Jichi Medical University, the National Cancer Center, Oita University, and the Tokyo Institute of Technology.

The business model is a traditional Japanese VC fund structure: revenue is generated from management fees and carried interest on successful portfolio exits. The firm has realized exits including SUSMED (TSE Growth IPO, December 2021), Noile-Immune Biotech (TSE Growth IPO, June 2023), CELLIAN-BiCLO (share sale, October 2023), and PRISM BioLab (TSE Growth IPO, July 2024). Multiple portfolio companies have established licensing or co-development relationships with major pharmaceutical companies including Takeda Pharmaceutical, Chugai Pharmaceutical, Otsuka Pharmaceutical, Eisai, Ohara Pharmaceutical, Daiichi Sankyo, Astellas/Xyphos, Genentech, Eli Lilly, Boehringer Ingelheim, Servier, Adaptimmune, Autolus, and PTC Therapeutics, creating multiple potential value-realization pathways. The firm's competitive position rests on the founders' deep industry networks and combined 40+ years of biotech investment, journalism, and policy experience.

Name

Healthcare Innovation

Legal name

株式会社ヘルスケア･イノベーション

Website

https://hcinnovation.jp

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Healthcare Innovation Co., Ltd. is a Tokyo-based venture capital firm founded in 2017 that manages the Healthcare Innovation First Fund, investing 70% in pre-IPO bio ventures and 30% in revolutionary technology ventures across Japan.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital services
• Biotech investment fund
• Healthcare venture funding
• Pre-IPO bio ventures
• Biotech capital investment

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Fund Management / VC Returns: Healthcare Innovation operates as a venture capital fund generating returns through capital gains on portfolio company exits (IPOs and M&A transactions). The fund takes management fees and carried interest from successful exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Healthcare Innovation operates a Japan-focused venture capital fund that invests in pre-IPO bio/healthcare ventures (70% of capital) and companies with breakthrough technology seeds (30%). The firm sources deals through a dedicated member portal, screens candidates from a pool of over 500 Japanese bio ventures, and provides capital plus hands-on support to portfolio companies through to IPO.

Product overview

Healthcare Innovation Co., Ltd. is a Japanese venture capital firm established in February 2017 by Yoshihiro Otaki and Mitsuru Miyata. The firm focuses on investing in and supporting bio/healthcare ventures, particularly those in the pre-IPO stage. The company's primary offering is its investment fund management business under the 'Healthcare Innovation First Fund', which targets bio ventures (70% of investment) and innovative technology ventures (30%). Healthcare Innovation also provides consultation and meeting application services through its member-exclusive portal site (member.hcinnovation.jp), where prospective portfolio companies can submit information for investment screening purposes.

Differentiator

Problem solved

Functional benefit

Brands

• Healthcare Innovation First Fund (ヘルスケア・イノベーション第一号ファンド): A venture capital fund targeting mid-stage biotech ventures in Japan. The fund aims to address Japan's bio-venture ecosystem deficiency, as approximately 40% of US bio-investments target the middle stage, while Japan lacks dedicated middle-stage biotech VCs.

Products and services

• Healthcare Innovation First Fund (ヘルスケア・イノベーション第一号ファンド) A venture capital fund targeting pre-IPO bio ventures (70% of allocation) and innovative technology ventures (30% of allocation). The fund aims to address gaps in Japan's bio venture ecosystem by focusing on middle-stage investments, distinguishing itself from conventional venture capital with a middle-risk, middle-return strategy. For bio/healthcare ventures seeking capital and growth support.

Quantifiable outcome

• 37 IPO exits and 12 M&A exits achieved by Chairman Yoshitaka Otaki
• +1 more outcomes

Named customers16 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

24 partnerships are on record, tiered minor and major.

• Yamaguchi University (Noile-Immune Biotech origin)minorStrategic or Co-development Partner · 1 February 2017Investment relationship with university-originated venture. Noile-Immune Biotech originated from Yamaguchi University researchers.
• Takeda Pharmaceutical (portfolio company licensing partner)majorStrategic or Co-development PartnerMultiple portfolio companies have licensing/partnership relationships with Takeda: Noile-Immune licensed PRIME CAR-T cells to Takeda; GEXVal is a Takeda spin-out; Takeda started clinical trials for two PRIME CAR-T types.
• Chugai Pharmaceutical (portfolio company partner)minorStrategic or Co-development PartnerNoile-Immune licensed PRIME CAR-T cells technology to Chugai Pharmaceutical.
• Otsuka Pharmaceutical (portfolio company partner)minorStrategic or Co-development PartnerRebirthel co-develops allogeneic CAR-T cells for blood cancers with Otsuka Pharmaceutical.
• Eisai (portfolio company partner)minorStrategic or Co-development PartnerPRISM BioLab licensed its Wnt signaling inhibitor to Eisai for anticancer drug development; progressed to Phase 2 trials.
• Ohara Pharmaceutical (portfolio company partner)minorStrategic or Co-development PartnerPRISM BioLab licensed its Wnt signaling inhibitor to Ohara Pharmaceutical for liver disease treatment; progressed to Phase 2 trials.
• Jichi Medical University (Gene Therapy Research Institution origin)minorStrategic or Co-development PartnerGene Therapy Research Institution maintains close relationship with Jichi Medical University for vector development and physician-led clinical trials.
• Kyoto University (Rebirthel origin)minorStrategic or Co-development PartnerRebirthel originated from Kyoto University researchers leading iPS cell-derived allogeneic CAR-T/TCR-T cell development.
• Osaka University (Luxna Biotech origin)minorStrategic or Co-development PartnerLuxna Biotech originated from Osaka University with proprietary cross-linked nucleic acid technology.
• Chiba University (CellGenTech origin)minorStrategic or Co-development PartnerCellGenTech originated from Chiba University researchers developing ex vivo gene therapy.
• National Cancer Center (ARC Therapies origin)minorStrategic or Co-development PartnerARC Therapies originated from the National Cancer Center developing next-generation CAR-T/TCR-T cells.
• Oita University (Oita University Institute of Advanced Medicine origin)minorStrategic or Co-development PartnerOita University Institute of Advanced Medicine originated from Oita University with proprietary chemical synthesis technology.
• Genentech (portfolio technology licensing)majorStrategic or Co-development PartnerPRISM BioLab licensed its mid-sized molecular library to Genentech (US) for drug development.
• Servier (portfolio technology licensing)minorStrategic or Co-development PartnerPRISM BioLab licensed its mid-sized molecular library to Servier (France) for drug development.
• Boehringer Ingelheim (portfolio technology licensing)minorStrategic or Co-development PartnerPRISM BioLab licensed its mid-sized molecular library to Boehringer Ingelheim (Germany) for drug development.
• Eli Lilly (portfolio technology licensing)minorStrategic or Co-development PartnerPRISM BioLab licensed its mid-sized molecular library to Eli Lilly (US) for drug development.
• Adaptimmune (portfolio licensing)minorStrategic or Co-development PartnerNoile-Immune licensed PRIME CAR-T technology to Adaptimmune (US) for development.
• Autolus (portfolio licensing)minorStrategic or Co-development PartnerNoile-Immune licensed PRIME CAR-T technology to Autolus (UK) for development.
• Astellas/Xyphos (portfolio partnership)minorStrategic or Co-development PartnerUnited Immunity is co-developing with Astellas' US subsidiary Xyphos on pullulan nanogel drug delivery technology.
• PTC Therapeutics (portfolio licensing)minorStrategic or Co-development PartnerGene Therapy Research Institution licensed Upstaza (AADC deficiency gene therapy) to US-based PTC Therapeutics, which received European Commission marketing authorization in July 2022.
• CAGE bio (portfolio partnership)minorStrategic or Co-development PartnerTAGCyx partnered with US-based CAGE bio for Xenoligo development against interferon-gamma for alopecia areata treatment.
• Daiichi Sankyo (portfolio partnership)minorStrategic or Co-development PartnerCureApp is developing digital therapeutics for cancer treatment in partnership with Daiichi Sankyo.
• Sawai Group Holdings (portfolio partnership)minorStrategic or Co-development PartnerCureApp is developing NASH digital therapeutics in partnership with Sawai Group Holdings.
• Tokyo Institute of Technology (AutoPhagyGO research foundation)minorStrategic or Co-development PartnerAutoPhagyGO develops therapeutics based on autophagy research by Nobel laureate Professor Yoshinori Ohsumi of Tokyo Institute of Technology.

Scale indicators5 records

Recent moves6 records

Expansion highlights3 records

Regional players

• World Innovation Lab (WiL): Japan-anchored, US-incorporated VC with healthcare and enterprise tech focus, including Japanese ventures. Comparable to HCI for Japanese bio deal flow exposure, though with cross-border mandate and larger fund size.
• Kyoto University Innovation Capital: Kyoto University-affiliated VC investing in bio/healthcare and deep tech spinouts. Directly comparable to HCI's university-originated portfolio companies (e.g., Rebirthel from Kyoto University) and represents the type of government-backed competitor entering the middle-stage bio space.
• UTokyo Innovation Platform: University-affiliated VC backed by the University of Tokyo, focused on deep tech and bio ventures from Japanese academia. Comparable as a Japan-based bio VC with university spinout deal flow — a segment HCI also targets (Rebirthel, Luxna Biotech, AutoPhagyGO origins).
• Osaka University Venture Capital: Osaka University-affiliated VC investing in bio/healthcare and other university-originated ventures. Comparable to HCI's portfolio company Luxna Biotech (Osaka University origin) and the broader university-bio VC niche HCI competes for deal flow in.

Emerging players

• ANRI: Tokyo-based early-stage VC with significant bio/healthcare and deep tech exposure. Comparable as a Japanese VC with life sciences portfolio companies and a similar stage orientation, though broader in sector focus.

Direct peers

• Beyond Next Ventures: Japan-based early-to-growth stage VC with a strong focus on life sciences and deep tech. Directly comparable as a bio/healthcare specialist VC investing in Japanese ventures, including university spinouts and pre-IPO biotech.
• DCI Partners: Tokyo-based PE firm with a dedicated focus on Japanese healthcare and life sciences investments across stages. Comparable as a Japan-based healthcare-focused investment firm, though DCI operates at a larger scale with buyout/control orientations.
• Fast Track Initiative: Tokyo-based VC focused on life sciences and healthcare ventures, including university-originated biotech. Comparable to HCI as a Japan-domiciled life sciences VC targeting bio ventures with growth potential.

Broad incumbents

• JAFCO Group: Japan's largest venture capital firm and a former employer of HCI's Chairman Yoshitaka Otaki. Directly comparable as a Japan-focused VC with significant bio/healthcare exposure, though JAFCO operates as a much larger, diversified generalist firm managing multiple funds and strategies.
• JIC Capital (formerly INCJ): Japan Investment Corporation's venture/growth arm, a government-backed investment platform with deep healthcare/biotech exposure. Comparable to HCI as a Japan-based bio investor but operating at vastly larger scale with policy mandate and patient capital.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healthcare Innovation